FY26 Financial Performance

Marksans Pharma achieved its highest-ever total income of ₹3,033.5 crore in FY26, representing 12.8% YoY growth. EBITDA reached ₹600.8 crore with a margin of 20.4%. Profit After Tax (PAT) stood at ₹420.1 crore, up 9.8% YoY. The company generated ₹458 crore cash from operations and ended the year with a cash balance of ₹990 crore.

Q4FY26 Financial Performance

Q4FY26 total income was ₹891.3 crore, up 23.1% YoY. Operating revenue stood at ₹856.1 crore. EBITDA reached ₹195.4 crore with a margin of 22.8%, expanding 491 basis points YoY. PAT was ₹149.0 crore, showing 64.3% YoY growth. Diluted EPS was ₹3.3 for the quarter.

Geographical Performance Breakdown

US & North America: Contributed 52% of FY26 revenue (₹1,533 crore), grew 24% YoY. 112 new SKUs launched in FY26 with 51 products in pipeline.

UK & Europe: Second largest market contributing 34% of revenue (₹1,015 crore). Q4FY26 achieved highest-ever quarterly revenue of ₹308 crore. Price erosion in UK products stabilized in Q4FY26. 18 products approved and 30 filings done in FY26.

Australia & New Zealand: Revenue of ₹303 crore in FY26, up 19.9% YoY. Launched branded prescription division Nova Pharma with 11 Rx brands launched in FY26. Q4FY26 revenue more than doubled sequentially to ₹123 crore.

Rest of World: Contributed 3% of revenue (₹99 crore), moderated 4.1% YoY due to geopolitical tensions in MENA and CIS regions.

Manufacturing Capabilities

Total manufacturing capacity of 26 billion units per annum across facilities in:

  • Farmingdale, USA: 6 billion tablets and hard gelatin capsules annually
  • Goa, India: 8 billion units capacity (6 billion tablets + 2.4 billion capsules)
  • Southport, UK: 2 billion bottles, 1 billion tubes, 1 billion sachets annually
  • Additional acquired facility in Goa with scalable capacity

Strategic Initiatives and Product Pipeline

The company is focusing on becoming the most reliable partner in the consumer healthcare space. Key strategies include increasing store brand penetration in North America, expanding product pipeline in OTC segment, and strengthening presence in key therapeutic segments including Pain Management, Upper Respiratory, Digestive and Anti-Allergic.

Product pipeline includes:

  • US: 51 products in pipeline
  • UK: 24 products awaiting approval as of 31 March 2026; 200+ products to be filed over next 4 years
  • Australia & New Zealand: 17 SKUs planned for FY27 across 22 products
  • Canada: 14 products filed during the year

Balance Sheet and Credit Rating

Cash balance of ₹990 crore as of 31st March 2026. Company has been net cash positive for over 5 years. Strong credit ratings: CARE AA- (Long term) and CARE A1+ (Short term) with stable outlook. Evaluating acquisitions in Europe region for front-end presence.

Shareholding Pattern

As of March 2026:

  • Promoters: 43.9%
  • FII/FPI: 16.8% (including OrbiMed Asia at 8.6%)
  • DII: 6.6%
  • Public & Others: 32.7%

Management Commentary

Mark Saldanha, Managing Director and CEO, stated: "FY26 has been a milestone year for Marksans Pharma. We successfully delivered on our guidance with highest-ever total income. Growth was led by a series of new launches across markets through the year. Our underlying momentum, balance sheet strength, and disciplined execution position us well to continue delivering sustainable growth and long-term shareholder value."